Scienture Holdings Stock Price, News & Analysis
Company Description
Scienture Holdings, Inc. (NASDAQ: SCNX) is a healthcare company that, through its wholly owned subsidiary Scienture, LLC, operates as a comprehensive pharmaceutical product business. According to company disclosures, Scienture focuses on providing enhanced value to patients, physicians and caregivers by developing, commercializing and distributing novel specialty pharmaceutical products that address unmet market needs. The company describes Scienture, LLC as a branded, specialty pharmaceutical organization staffed by experienced industry professionals who are focused on bringing unique specialty products to market for patients and healthcare systems.
Scienture Holdings, Inc. is incorporated in Delaware and maintains principal executive offices in Commack, New York, as reflected in its SEC filings. Its common stock trades on the Nasdaq Capital Market under the ticker symbol SCNX. The company is positioned within the healthcare sector and is associated with pharmaceutical product development and commercialization rather than traditional retail pharmacy operations.
Business focus and product portfolio
Across multiple press releases, Scienture states that its assets in development span therapeutic areas, indications and market segments. A key area of activity is cardiovascular care, where Scienture has introduced Arbli™, a proprietary oral suspension formulation of losartan potassium. Company communications describe Arbli™ as the first U.S. Food and Drug Administration (FDA)-approved, ready-to-use oral suspension formulation of losartan potassium and the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli™ is characterized as a novel proprietary formulation of losartan, an angiotensin II receptor blocker (ARB) widely prescribed for hypertension.
Arbli™ is indicated for the treatment of hypertension in adults and children greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes and a history of hypertension. Company descriptions emphasize that Arbli™ provides a safe, effective and convenient liquid alternative for patients who require or prefer a liquid formulation, and that as an FDA-approved product it offers consistent quality and dosing accuracy compared with extemporaneously compounded losartan prescriptions. Scienture notes that Arbli™ has two issued U.S. patents listed in the FDA Orange Book.
In addition to Arbli™, Scienture has secured exclusive U.S. commercialization rights to REZENOPY™ (naloxone HCl) Nasal Spray 10 mg under an agreement with Summit Biosciences Inc., a subsidiary of Kindeva Drug Delivery L.P. REZENOPY™ is described in company news as an opioid antagonist nasal spray indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for intranasal administration as emergency therapy in settings where opioids may be present. The product is supplied as a carton containing two blister packages, each with a single spray device.
Scienture’s communications state that REZENOPY™ is the highest dosage naloxone HCl nasal spray approved by the FDA and that it leverages the established naloxone hydrochloride molecule and a familiar nasal spray form factor while delivering increased effectiveness against potent opioids. The company highlights that REZENOPY™ received FDA approval on April 19, 2024. Scienture has disclosed that, subject to certain commercial obligations, it expects to own the new drug application (NDA) for REZENOPY™ in its name and to be responsible for sales, marketing and distribution in the United States through its commercial operations infrastructure, while Summit will manufacture and supply the product.
Therapeutic areas and market context
Through Arbli™, Scienture participates in the U.S. losartan market, which company press releases, citing IQVIA data, describe as totaling approximately hundreds of millions of dollars in annual sales with tens of millions of prescriptions each year. Scienture characterizes this as a significant commercial opportunity, particularly for patients who need an alternative to solid dosage forms. The company has reported steps to expand access to Arbli™, including commercial availability through full-line wholesalers nationwide and the addition of Arbli™ to the formularies of major national health plans, which it states extends access to a large number of covered lives across the United States. Scienture has also announced multiple commercial group purchasing organization (GPO) agreements providing access to thousands of healthcare institutions, including hospitals, clinics, nursing homes, specialty pharmacies, long-term care facilities and ambulatory centers.
With REZENOPY™, Scienture is active in the U.S. naloxone market. Company materials, again referencing IQVIA data, describe this market in terms of annual sales and unit volumes and present REZENOPY™ as addressing a critical public health need related to opioid overdose. Scienture highlights that REZENOPY™ is intended for emergency treatment of opioid overdose and that it may be particularly relevant where potent opioids are involved or where multiple doses of lower-strength naloxone are often required.
Intellectual property and regulatory positioning
Scienture’s strategy, as described in its news releases, includes securing intellectual property protection and regulatory approvals for its specialty products. For Arbli™, the company notes that two issued U.S. patents are listed in the FDA Orange Book. For REZENOPY™, Scienture has announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,514,854 B2, an Orange Book-listable patent covering REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, effective January 6, 2026, with an expiry date of February 5, 2041. The company states that this patent, if listed in the FDA’s Orange Book, may provide additional intellectual property protection supporting U.S. commercialization.
Company statements describe Orange Book-listable patents as an important component of product lifecycle management and indicate that such protection is viewed as supporting long-term commercial strategy. Scienture’s disclosures also emphasize that its assets in development span therapeutic areas and indications and are intended to serve different market segments and channels, though specific pipeline products beyond Arbli™ and REZENOPY™ are not detailed in the provided materials.
Corporate structure, capital markets and governance
Scienture Holdings, Inc. functions as a holding company for existing and planned pharmaceutical operating companies. Scienture, LLC is identified as a wholly owned subsidiary and the branded, specialty pharmaceutical operating entity. SEC filings show that the company files reports with the U.S. Securities and Exchange Commission under Commission File Number 001-39199 and that it has used a shelf registration on Form S-3 to facilitate equity offerings. In 2025, the company filed prospectus supplements to an existing Form S-3 registration statement in connection with an equity distribution agreement, describing potential aggregate offering amounts of common stock under General Instruction I.B.6 of Form S-3.
Scienture has also disclosed financing arrangements in its current reports on Form 8-K, including secured promissory notes and prior secured convertible debentures, as well as subsequent amendments and conversions that affected its capital structure. One 8-K describes a letter agreement under which outstanding balances on secured convertible debentures issued to certain investors were converted into common stock, with related security interests and obligations terminated upon full conversion. Another 8-K details a senior secured promissory note with an original issue discount, secured by security agreements granting a security interest in the assets of the company and Scienture, LLC, and guaranteed by Scienture, LLC.
In corporate governance matters, Scienture’s definitive proxy statement and related 8-K filings describe its annual meeting of stockholders, proposals submitted to stockholders and amendments to its bylaws. In October 2025, the board approved an amendment to the company’s bylaws changing the quorum requirement for stockholder meetings from a majority of voting stock to one-third of the voting stock, unless otherwise required by law, the certificate of incorporation or the bylaws. At the 2025 annual meeting, stockholders voted on proposals including the election of directors, changes to authorized share capital, amendments to the company’s equity incentive plan, authorization for a potential future offering of common stock under Nasdaq Listing Rule 5635(d), authorization for a reverse stock split within a specified range, and potential adjournment of the meeting.
Listing status and regulatory notices
Scienture has reported receiving a notice from the Nasdaq Listing Qualifications department regarding non-compliance with Nasdaq Listing Rule 5450(a)(1), which requires a minimum bid price of at least $1.00 per share. The notice, dated October 14, 2025, indicated that the company’s common stock had traded below $1.00 per share for 30 consecutive business days. According to the company’s 8-K, Scienture was afforded a 180-calendar day grace period, until April 13, 2026, to regain compliance by maintaining a minimum bid price of at least $1.00 per share for a required period. The company stated that the notice had no immediate effect on the listing or trading of its common stock on Nasdaq and expressed its belief that it would be able to regain compliance, while noting that there could be no assurance of such an outcome.
Position within the healthcare and pharmaceutical landscape
Based on its own descriptions, Scienture’s business model centers on branded, specialty pharmaceutical products that aim to address unmet clinical and practical needs, particularly where existing therapies may require compounding or are not available in certain formulations. Arbli™ targets patients who need a ready-to-use oral suspension of losartan potassium, and REZENOPY™ targets emergency treatment of opioid overdose with a high-strength naloxone nasal spray. The company emphasizes patient-centric attributes such as convenience, dosing accuracy and access through established distribution and payer channels.
Scienture’s disclosures indicate that it seeks to build a commercial infrastructure capable of supporting multiple products across therapeutic areas and channels, including retail, institutional and long-term care settings. Its agreements with manufacturing partners, wholesalers, group purchasing organizations, health plans and patient access platforms are presented as mechanisms to broaden distribution and utilization of its specialty products within the U.S. healthcare system.